Hidrocloruro De Petidina Altan (Pethidine Hydrochloride)

Hidrocloruro De Petidina Altan is indicated for short‑term relief of pain that is moderate to severe and requires opioid therapy.

• Management of moderate to severe acute pain, such as trauma or injury.
• Post‑operative analgesia following surgical procedures.
• Labor analgesia when rapid pain control is needed.
• Adjunctive analgesia in patients with severe pain unresponsive to non‑opioid agents.
• Short‑term use in emergency settings for breakthrough pain.

• Pethidine hydrochloride acts as an agonist at the µ‑opioid receptors in the central nervous system. Binding to these G‑protein‑coupled receptors inhibits adenylate cyclase activity, reduces calcium influx, and increases potassium efflux, which collectively diminish neuronal excitability and suppress transmission of nociceptive signals. The resulting effect is analgesia comparable to other opioid agents, with a relatively rapid onset when administered intravenously or intramuscularly.

Adverse reactions to Hidrocloruro De Petidina Altan vary in frequency and severity.

Common

• Nausea and vomiting
• Dizziness or light‑headedness
• Sweating or flushing
• Constipation
• Mild respiratory depression

Serious

• Severe respiratory depression leading to hypoxia
• Marked hypotension or cardiovascular collapse
• Seizures or convulsions
• Anaphylactic or severe allergic reactions

When prescribing Hidrocloruro De Petidina Altan, clinicians should consider several safety factors.

• Assess the patient for risk of opioid dependence or abuse before initiating therapy.
• Monitor respiratory function closely, especially after intravenous administration.
• Use with caution in elderly or debilitated patients who may be more sensitive to sedative effects.
• Adjust dosing or avoid use in patients with significant hepatic or renal impairment.
• Pregnancy category is unknown; avoid use unless the benefit outweighs potential risk.
• Contraindicated in patients with severe asthma or uncontrolled respiratory disease.
• Educate patients about the signs of overdose and the importance of adhering to prescribed dosing.

Hidrocloruro De Petidina Altan can interact with other medications, affecting safety and efficacy.

Avoid

• Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI therapy.
• Co‑administration with other opioids, benzodiazepines, or central nervous system depressants due to additive respiratory depression.
• Alcohol or illicit substances that depress the central nervous system.
• Certain selective serotonin reuptake inhibitors (SSRIs) that may increase the risk of serotonin syndrome.

Use with caution

• Benzodiazepines and barbiturates; monitor for enhanced sedation.
• Antihistamines or other sedating antihistamines; observe for increased drowsiness.
• CYP3A4 inhibitors (e.g., erythromycin, ketoconazole) which may raise pethidine plasma levels.
• Drugs that affect cardiac conduction (e.g., quinidine) as pethidine can prolong QT interval.
• Medications that lower seizure threshold; monitor for seizure activity.